Tech Company Financing Transactions
Gallant Funding Round
On 7/1/2025, Gallant raised $18 million in Series B investment from Digitalis Ventures, Bold Capital Partners and NovaQuest.
Transaction Overview
Company Name
Announced On
7/1/2025
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to accelerates its path to initial commercial rollout of its lead product for FCGS, while advancing a pipeline of therapies for Canine and Feline Osteoarthritis (COA and FOA), Canine Atopic Dermatitis (CAD), and Feline Chronic Kidney Disease (CKD), conditions where current standards of care manage symptoms rather than address the underlying disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
12130 Millennium Dr.
Los Angeles, CA 90094
USA
Los Angeles, CA 90094
USA
Phone
Website
Email Address
Overview
The Gallant team is a collective of respected veterinarians, scientists, and some unbelievably dedicated entrepreneurs. Our work is the result of over 100 years of regenerative medicine experience, and a commitment to invest millions into the future of stem cell therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Aaron Hirschhorn
Chief Medical Officer
Shelly Zacharias
President
Linda Black
Browse more venture capital transactions:
Prev: 6/30/2025: Levelpath venture capital transaction
Next: 7/1/2025: Field Medical venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs